Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering ... FDA priority review, comes after more than ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

Now, the nasal spray can be used on its own. “This really makes the therapy so much more accessible to patients,” Haviva Malina, MD, co-founder of the ketamine infusion clinic Keta Medical Center, ...

Spravato, which is derived from ketamine ... patients need to be treated in a doctor’s office or hospital setting and remain in the clinic until the side effects have passed. The nasal spray ...

22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living ... granted following FDA priority review, was based on the ...